BUSINESS● LOWSep 12 · Sep 12, 2026, 4:57 PM
Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Yahoo Finance · global
No summary available — read the full story at the source.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS29m agoNew episode: The real story behind Mexico’s record exportsMexico News DailyBUSINESS29m agoAlphabet’s record plunge, Intel’s 30% collapse: tech’s brutal week of reckoningSeeking Alpha Tech